MCRB SERES THERAPEUTICS INC Expansion Plans 8-K Filing 2024 - SER-155 Study Results Seres Therapeutics announced positive results from its SER-155 Phase 1b study, showing significant reductions in bloodstream infections and antibiotic use in patients undergoing stem cell transplantation, and plans to seek FDA Breakthrough Therapy designation.Get access to all SEC 8-K filings of the SERES THERAPEUTICS INC